Cascadian Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CASC and buy or sell other stocks, ETFs, and their options commission-free!About CASC
Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin.
CEOScott D. Myers, MBA
CEOScott D. Myers, MBA
Employees—
Employees—
HeadquartersBothell, Washington
HeadquartersBothell, Washington
Founded2007
Founded2007
Employees—
Employees—
CASC Key Statistics
Market cap507.00M
Market cap507.00M
Price-Earnings ratio-8.28
Price-Earnings ratio-8.28
Dividend yield—
Dividend yield—
Average volume339.82K
Average volume339.82K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$10.21
52 Week high$10.21
52 Week low$3.18
52 Week low$3.18
Stock Snapshot
Cascadian Therapeutics(CASC) stock is priced at $10.02, giving the company a market capitalization of 507M. It carries a P/E multiple of -8.28.
During the trading day, Cascadian Therapeutics(CASC) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading volume for Cascadian Therapeutics(CASC) stock has reached 0, versus its average volume of 339.82K.
The stock's 52-week range extends from a low of $3.18 to a high of $10.21.
The stock's 52-week range extends from a low of $3.18 to a high of $10.21.